CELZ: 分析师目标 $20 — AI 分析 (4月 2026)

Creative Medical Technology Holdings, Inc. is a biotechnology company focused on developing adult stem cell treatments for various conditions. Their product pipeline targets unmet needs in immunology, urology, orthopedics, and neurology.

Key Facts: Price: $2.04 Analyst Target: $20.00 AI Score: 52/100 Sector: Healthcare

公司概况

概要：

Creative Medical Technology Holdings pioneers stem cell therapies targeting large markets like erectile dysfunction, infertility, and chronic pain, offering potential for significant growth in the regenerative medicine space despite inherent biotechnology risks and limited current revenue.

CELZ是做什么的？

Creative Medical Technology Holdings, Inc., headquartered in Phoenix, Arizona, is a biotechnology company dedicated to the development of novel adult stem cell therapies. The company focuses on addressing unmet medical needs in areas such as immunology, urology, orthopedics, and neurology. Creative Medical Technology Holdings aims to leverage the regenerative potential of adult stem cells to create innovative treatments for a range of debilitating conditions. Their product pipeline includes CaverStem, a treatment for erectile dysfunction; FemCelz, designed to address loss of genital sensitivity and dryness in women; StemSpine, a therapy for chronic lower back pain; ImmCelz, a treatment being developed for stroke patients; and OvaStem, which targets female infertility. The company's approach centers around harnessing the body's own healing mechanisms to restore function and improve patient outcomes. Founded with the vision of transforming healthcare through regenerative medicine, Creative Medical Technology Holdings continues to advance its research and development efforts, seeking to bring its innovative therapies to market and improve the lives of patients worldwide. The company operates in the competitive biotechnology landscape, navigating the challenges of clinical trials, regulatory approvals, and commercialization. Their success hinges on the efficacy and safety of their stem cell therapies, as well as their ability to secure funding and partnerships to support their ongoing development programs. The company's commitment to innovation and its focus on addressing significant unmet medical needs position it as a potentially disruptive force in the regenerative medicine field.

CELZ的投资论点是什么？

Creative Medical Technology Holdings presents a speculative investment opportunity within the high-risk, high-reward biotechnology sector. The company's focus on adult stem cell therapies targeting large markets such as erectile dysfunction (CaverStem) and infertility (OvaStem) offers significant potential upside if clinical trials are successful and regulatory approvals are obtained. However, the company's current financial metrics, including a negative profit margin of -99356.8% and gross margin of -452.4%, highlight the pre-revenue nature of the business and the substantial cash burn associated with biotechnology research and development. Key value drivers include successful clinical trial outcomes for its lead product candidates and strategic partnerships to accelerate commercialization. Upcoming clinical trial milestones and potential FDA approvals represent significant catalysts for the stock. Investors should carefully consider the inherent risks associated with biotechnology investing, including regulatory hurdles, clinical trial failures, and the need for additional capital raises.

CELZ在哪个行业运营？

Creative Medical Technology Holdings operates within the competitive and rapidly evolving biotechnology industry. The regenerative medicine market, which includes stem cell therapies, is projected to experience significant growth in the coming years, driven by increasing demand for innovative treatments for chronic diseases and age-related conditions. The company faces competition from established pharmaceutical companies and other biotechnology firms developing similar therapies. Key industry trends include advancements in stem cell technology, increasing regulatory scrutiny, and the growing importance of personalized medicine. Competitors like ACXP, ADIL, ADXN, ALZN, and APRE are also vying for market share in the broader biotechnology space, though not all are directly focused on stem cell therapies.

Biotechnology

Healthcare

CELZ有哪些增长机遇？

CaverStem for Erectile Dysfunction: The erectile dysfunction market represents a significant opportunity for Creative Medical Technology Holdings. CaverStem, their stem cell therapy for ED, could capture a substantial share of this market if proven safe and effective. The global erectile dysfunction market is projected to reach billions of dollars in the coming years, driven by an aging population and increasing awareness of treatment options. Successful clinical trials and regulatory approval for CaverStem could be a major growth driver for the company, potentially within the next 3-5 years.
FemCelz for Female Sexual Dysfunction: FemCelz targets the underserved market of female sexual dysfunction, specifically addressing loss of genital sensitivity and dryness. This market presents a significant growth opportunity, as many women experience these issues, and effective treatments are limited. Positive clinical trial results and subsequent commercialization of FemCelz could lead to substantial revenue growth for Creative Medical Technology Holdings. This opportunity could materialize within the next 3-5 years, pending clinical trial progress.
StemSpine for Chronic Lower Back Pain: Chronic lower back pain affects a large segment of the population, creating a substantial market for effective treatments. StemSpine, the company's stem cell therapy for chronic lower back pain, has the potential to alleviate pain and improve function for patients who have not responded to conventional therapies. Success in clinical trials and regulatory approval could position StemSpine as a valuable treatment option and a significant revenue generator for the company over the next 3-5 years.
ImmCelz for Stroke Patients: ImmCelz, the company's stem cell therapy for stroke patients, targets a critical unmet need. Stroke is a leading cause of disability, and effective treatments to promote recovery are limited. If ImmCelz demonstrates efficacy in clinical trials, it could become a valuable therapy for stroke patients and a significant growth driver for Creative Medical Technology Holdings. This opportunity is likely 3-5 years out, contingent on successful clinical development.
OvaStem for Female Infertility: OvaStem aims to address female infertility, a growing concern worldwide. The company's stem cell therapy has the potential to improve egg quality and increase the chances of successful conception. The global fertility market is expanding, driven by factors such as delayed childbearing and increasing access to fertility treatments. Successful development and commercialization of OvaStem could provide a significant growth opportunity for Creative Medical Technology Holdings in the next 3-5 years.

Market Cap of $0.00B reflects the company's micro-cap status and early stage of development.
P/E Ratio of -0.77 indicates the company is currently not profitable.
Profit Margin of -99356.8% highlights significant losses due to ongoing research and development expenses.
Gross Margin of -452.4% reflects the high cost of research and development relative to any current revenue.
Beta of 2.07 suggests the stock is more volatile than the overall market.

CELZ提供哪些产品和服务？

Develop stem cell therapies for erectile dysfunction (CaverStem).
Develop stem cell therapies for female sexual dysfunction (FemCelz).
Develop stem cell therapies for chronic lower back pain (StemSpine).
Develop stem cell therapies for stroke patients (ImmCelz).
Develop stem cell therapies for female infertility (OvaStem).
Focus on regenerative medicine using adult stem cell treatments.
Conduct research and development in immunology, urology, orthopedics, and neurology.

CELZ如何赚钱？

Develops and patents stem cell therapy technologies.
Conducts preclinical and clinical trials to evaluate the safety and efficacy of its therapies.
Seeks regulatory approvals from agencies like the FDA.
Aims to commercialize its therapies through partnerships or direct sales.

Patients suffering from erectile dysfunction.
Women experiencing loss of genital sensitivity and dryness.
Individuals with chronic lower back pain.
Stroke patients seeking improved recovery.
Women struggling with infertility.

Proprietary stem cell therapy technologies.
Patents protecting its therapeutic candidates.
First-mover advantage in specific stem cell therapy applications.
Expertise in regenerative medicine and stem cell biology.

什么因素可能推动CELZ股价上涨？

Upcoming: Clinical trial results for CaverStem in 2026.
Upcoming: Clinical trial results for FemCelz in 2026.
Upcoming: FDA approval decisions for lead product candidates.
Ongoing: Progress in research and development of new stem cell therapies.
Ongoing: Strategic partnerships to accelerate commercialization.

CELZ的主要风险是什么？

Potential: Clinical trial failures could significantly impact the company's prospects.
Potential: Regulatory delays or rejections could hinder the commercialization of its therapies.
Ongoing: The company may need to raise additional capital, potentially diluting existing shareholders.
Ongoing: Competition from larger pharmaceutical companies with greater resources.
Ongoing: The biotechnology industry is subject to rapid technological advancements, which could render the company's therapies obsolete.

CELZ的核心优势是什么？

Proprietary stem cell therapy technologies.
Diverse product pipeline targeting multiple therapeutic areas.
Focus on unmet medical needs.
Experienced management team in regenerative medicine.

CELZ的劣势是什么？

Limited financial resources.
Pre-revenue stage company.
High dependence on clinical trial outcomes.
Small number of employees.

CELZ有哪些机遇？

Partnerships with larger pharmaceutical companies.
Expansion into new therapeutic areas.
Accelerated regulatory pathways for regenerative medicine.
Growing demand for stem cell therapies.

CELZ面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established pharmaceutical companies.
Need for additional capital raises.

CELZ的竞争对手是谁？

Accelerate Diagnostics, Inc. — Focuses on rapid diagnostics for infectious diseases. — (ACXP)
Adial Pharmaceuticals, Inc. — Developing therapies for addiction. — (ADIL)
Addex Therapeutics Ltd — Developing allosteric modulators for neurological disorders. — (ADXN)
Alzamend Neuro, Inc. — Focuses on treatments for Alzheimer's disease. — (ALZN)
Aprea Therapeutics, Inc. — Developing cancer therapies. — (APRE)

Key Metrics

Price: $2.04 (+5.15%)
Market Cap: $6.0M
MoonshotScore: 52/100

Analyst Price Target

Analyst Consensus Target: $20.00
Current Price: $2.04
Implied Upside: +880.4%

常见问题

What does Creative Medical Technology Holdings, Inc. (CELZ) do?

Creative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company that focuses on developing adult stem cell treatments for various conditions. Their primary focus is on regenerative medicine, with a pipeline of products targeting unmet needs in areas such as urology, orthopedics, immunology, and neurology. CELZ aims to harness the body's own healing mechanisms to restore function and improve patient outcomes through innovative stem cell therapies like CaverStem for erectile dysfunction and OvaStem for female infertility.

Is CELZ stock a good buy?

Evaluating whether CELZ stock is a good buy requires careful consideration of its high-risk, high-reward profile. The company's negative profit margin and pre-revenue status indicate significant financial risk. However, successful clinical trials and regulatory approvals for its stem cell therapies could lead to substantial gains. Investors should weigh the potential upside against the inherent risks of biotechnology investing, including regulatory hurdles, clinical trial failures, and the need for additional capital raises. A thorough assessment of the company's pipeline and financial position is crucial before making an investment decision.

What are the risks of investing in CELZ?

Investing in Creative Medical Technology Holdings (CELZ) carries significant risks inherent to the biotechnology industry and the company's stage of development. A primary risk is the potential for clinical trial failures, which could halt the development of its therapies and negatively impact the stock price. Regulatory hurdles and delays in obtaining FDA approvals also pose a threat. Furthermore, CELZ may require additional capital raises, potentially diluting existing shareholders. Competition from larger pharmaceutical companies with greater resources is another factor to consider. These risks should be carefully evaluated before investing in CELZ.

What catalysts could move CELZ stock?

Several catalysts could potentially move CELZ stock in the near future. Positive clinical trial results for its lead product candidates, such as CaverStem and FemCelz, would likely drive investor interest and increase the stock price. FDA approval decisions for its therapies represent significant milestones that could lead to substantial gains. Strategic partnerships with larger pharmaceutical companies could also provide a boost to the stock. Additionally, any progress in the research and development of new stem cell therapies could serve as a positive catalyst.

What is CELZ stock price target?

As of March 2, 2026, there is no readily available analyst consensus price target for CELZ stock due to its micro-cap status and limited analyst coverage. Given the speculative nature of the company and its pre-revenue stage, a fair value estimate would be highly subjective and dependent on the perceived probability of success for its clinical trials and regulatory approvals. Investors should conduct their own due diligence and consider the inherent risks and uncertainties before making an investment decision.